[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch1][C][C][C][=Branch1][C][=O][O][C][C@@H1][C@H1][Branch2][Ring1][=Branch2][C@H1][Branch2][Ring1][Ring2][C@@H1][Branch1][Ring2][O][Ring1][Branch1][N][C][=C][C][=Branch1][=Branch1][=N][C][Ring1][=Branch1][=O][N][O][O][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication."}]